SG
IBB icon

Sharper & Granite’s iShares Biotechnology ETF IBB Stock Holding History

Sharper & Granite’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$970K Sell
5,099
-10
-0.2% -$1.72K 0.3% 69
2026
Q1 		$863K Sell
5,109
-300
-6% -$51.3K 0.29% 69
2025
Q4 		$913K Sell
5,409
-365
-6% -$59.3K 0.32% 67
2025
Q3 		$834K Sell
5,774
-1,806
-24% -$247K 0.3% 67
2025
Q2 		$982K Buy
7,580
+1,410
+23% +$173K 0.37% 68
2025
Q1 		$789K Sell
6,170
-80
-1% -$10.8K 0.33% 66
2024
Q4 		$826K Buy
6,250
+170
+3% +$23.9K 0.36% 68
2024
Q3 		$885K Buy
6,080
+365
+6% +$52.8K 0.4% 63
2024
Q2 		$784K Buy
5,715
+115
+2% +$15.4K 0.37% 66
2024
Q1 		$742K Sell
5,600
-175
-3% -$23.9K 0.36% 67
2023
Q4 		$785K Buy
5,775
+155
+3% +$18.9K 0.41% 65
2023
Q3 		$687K Buy
5,620
+185
+3% +$23.5K 0.4% 66
2023
Q2 		$690K Buy
5,435
+95
+2% +$12.3K 0.4% 65
2023
Q1 		$690K Sell
5,340
-85
-2% -$11.1K 0.41% 65
2022
Q4 		$712K Buy
+5,425
New +$701K 0.47% 61

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
MCG
McCollum Christoferson Group Amherst, New York $341M AUM 15.01% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SCA
Southern Capital Advisors Jackson, Tennessee $239M AUM 22.42% 1-Year Est. Return

Sharper & Granite's IBB Position: Q2 2026 in Review

Sharper & Granite reduced its iShares Biotechnology ETF (IBB) stake by 0.2% in Q2 2026, selling an estimated $1.72K and leaving 5,099 shares worth $970K. The position accounts for 0.3% of the portfolio, ranked #69.

Sharper & Granite first reported a position in IBB in Q4 2022 and has held it in 15 quarters since. The position peaked at $982K in Q2 2025. 158 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Sharper & Granite held 5,099 shares of iShares Biotechnology ETF worth $970K as of Q2 2026.
  • Sharper & Granite sold 10 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.72K.
  • iShares Biotechnology ETF made up 0.3% of Sharper & Granite's portfolio in Q2 2026, its #69 holding.
  • Sharper & Granite first reported a position in iShares Biotechnology ETF in Q4 2022 and has held it in 15 quarters since.
  • Sharper & Granite's iShares Biotechnology ETF position peaked at $982K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Sharper & Granite's 13F filing for Q2 2026, filed 16 Jul 2026.